immuno-oncology

News

Merck gets EU approval for Keytruda in triple-negative breas...

Merck & Co has claimed EU approval for Keytruda in triple-negative breast cancer (TNBC), a particularly hard-to-treat form of the disease.

News

BMS strikes back against Merck in EU oesophageal cancer mark...

Merck & Co's Keytruda become the first cancer immunotherapy to be approved as a first-line oesophageal cancer treatment in the EU earlier this year, but will now face competition from B

News

UK startup Leucid raises £11.5m for solid tumour CAR-T thera...

CAR-T therapies have revolutionised the treatment of some blood cancers, but so far haven't been able to repeat that success in solid tumours.

News

Good news for Lilly as sintilimab hits the spot in lung canc...

Eli Lilly made a late entry into the checkpoint inhibitor market when it licensed ex-China rights to Innovent's sintilimab last year, and a new trial in lung cancer will raise its hopes of

News

Roche scores adjuvant lung cancer approval for Tecentriq

Roche has claimed an earlier-than-expected FDA approval for its checkpoint inhibitor Tecentriq in non-small cell lung cancer (NSCLC), giving the drug a lead in early-stage cases that can be

Events